全文获取类型
收费全文 | 27143篇 |
免费 | 2763篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 262篇 |
儿科学 | 831篇 |
妇产科学 | 650篇 |
基础医学 | 3711篇 |
口腔科学 | 613篇 |
临床医学 | 3248篇 |
内科学 | 5501篇 |
皮肤病学 | 392篇 |
神经病学 | 2658篇 |
特种医学 | 810篇 |
外科学 | 3455篇 |
综合类 | 617篇 |
一般理论 | 22篇 |
预防医学 | 2989篇 |
眼科学 | 548篇 |
药学 | 2232篇 |
1篇 | |
中国医学 | 31篇 |
肿瘤学 | 1358篇 |
出版年
2021年 | 472篇 |
2020年 | 276篇 |
2019年 | 457篇 |
2018年 | 522篇 |
2017年 | 425篇 |
2016年 | 417篇 |
2015年 | 462篇 |
2014年 | 654篇 |
2013年 | 936篇 |
2012年 | 1366篇 |
2011年 | 1430篇 |
2010年 | 785篇 |
2009年 | 648篇 |
2008年 | 1163篇 |
2007年 | 1325篇 |
2006年 | 1221篇 |
2005年 | 1259篇 |
2004年 | 1130篇 |
2003年 | 1166篇 |
2002年 | 1054篇 |
2001年 | 699篇 |
2000年 | 699篇 |
1999年 | 608篇 |
1998年 | 297篇 |
1997年 | 240篇 |
1996年 | 222篇 |
1995年 | 257篇 |
1994年 | 236篇 |
1992年 | 522篇 |
1991年 | 486篇 |
1990年 | 463篇 |
1989年 | 458篇 |
1988年 | 415篇 |
1987年 | 420篇 |
1986年 | 371篇 |
1985年 | 437篇 |
1984年 | 375篇 |
1983年 | 297篇 |
1982年 | 287篇 |
1981年 | 234篇 |
1980年 | 238篇 |
1979年 | 346篇 |
1978年 | 295篇 |
1977年 | 208篇 |
1976年 | 242篇 |
1975年 | 212篇 |
1974年 | 273篇 |
1973年 | 284篇 |
1972年 | 232篇 |
1971年 | 213篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Richard A. Lewis 《Journal of cataract and refractive surgery》2019,45(7):1051-1052
4.
Oga Emmanuel. A. Peters Erica. N. Mark Katrina Trocin Kathleen Coleman-Cowger Victoria. H. 《Maternal and child health journal》2019,23(2):250-257
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents... 相似文献
5.
6.
7.
8.
Matthew D. Li Katrina F. Chu Allegra DePietro Vincent Wu Eric Wehrenberg-Klee Omar Zurkiya Raymond W. Liu Suvranu Ganguli 《Journal of vascular and interventional radiology : JVIR》2019,30(3):314-319
Purpose
To evaluate the feasibility of a same-day yttrium-90 (90Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases.Materials and Methods
All same-day radioembolization procedures performed over 1 y (February 2017 to January 2018) were included in this single-institutional retrospective analysis, in which 34 procedures were performed in 26 patients (median age, 63 y; 13 women), 19 with liver metastases and 7 with HCC. Yttrium-90 treatment activities were calculated by body surface area method. Tumor imaging response was assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for liver metastases and modified RECIST for HCC. Clinical side effects and adverse events were graded per Common Terminology Criteria for Adverse Events version 4.0.Results
All planned cases were technically successful, and no cases were canceled for elevated LSF or vascular anatomic reasons. Pretreatment angiography modified the planned 90Y treatment activity in 1 case in which vascular anatomy required a lobar-dose split into 2 for segmental infusions. In 18% of cases, patients were briefly admitted after the procedure for observation or symptom management. Imaging evaluation of initial efficacy at 1 month demonstrated partial response in 25% and stable disease in 67% of patients with liver metastases and partial/complete response in 43% and stable disease in 14% of patients with HCC. Grade ≥ 3 adverse events occurred in 6% of cases, with no systemic therapy–limiting toxicities. The mean total procedure time was 4.2 hours.Conclusions
A same-day 90Y radioembolization protocol with resin microspheres is feasible in select patients, which can expedite cancer therapy. 相似文献9.
Matthew S Lewis Paul Maruff Brendan S Silbert Lis A Evered David A Scott 《Archives of clinical neuropsychology》2006,21(5):421-427
The reliable change index (RCI) expresses change relative to its associated error, and is useful in the identification of post-operative cognitive dysfunction (POCD). This paper examines four common RCIs that each account for error in different ways. Three rules incorporate a constant correction for practice effects and are contrasted with the standard RCI that had no correction for practice. These rules are applied to 160 patients undergoing coronary artery bypass graft (CABG) surgery who completed neuropsychological assessments preoperatively and 1 week post-operatively using error and reliability data from a comparable healthy non-surgical control group. The rules all identify POCD in a similar proportion of patients, but the use of the within subject standard deviation, expressing the effects of random error, as an error estimate is a theoretically appropriate denominator when a constant error correction, removing the effects of systematic error, is deducted from the numerator in a RCI. 相似文献
10.
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients 总被引:1,自引:0,他引:1
R H Kerman C T Van Buren R M Lewis V DeVera V Baghdahsarian K Gerolami B D Kahan 《Transplantation》1990,49(1):52-56
We compared our standard NIH (extended incubation) crossmatch (XM) with antihuman globulin (AHG) and flow cytometry XMs and correlated the results with rejection episodes and graft survivals. For 89 CsA-Pred, primary renal allograft recipients, AHG and/or FCXM results did not improve on the NIH-XM-negative (NEG) graft survival results, whether testing pretransplant or historical (Hx) sera. Similarly, there was no association of a positive (POS) AHG or FCXM with increased rejection episodes in these primary recipients. However, for retransplant (Re-Tx) recipients a neg AHG or FCXM did discriminate fewer rejections and an improved graft survival compared with the NIH-XM-neg. results. The overall one-year graft survival for the 47 Re-Tx recipients studied herein was 66% (based on a neg pre-Tx NIH-XM). Pre-Tx AHG-NEG, Re-Tx recipients displayed an improved graft survival compared with NIH-XM NEG recipients (77% vs. 66%, P less than 0.05) and with AHG-POS recipients (77% vs. 47%, P less than 0.05). Similarly, pre-Tx, FCXM-NEG, Re-Tx recipients displayed improved graft survivals compared with NIH-XM-NEG recipients (83% vs. 66%, P less than 0.05) and FCXM-POS recipients (83% vs. 48%, P less than 0.05). Re-Tx recipients displaying a POS AHG and/or FCXM experienced a significantly greater number of rejections than NEG-XM recipients (P less than 0.05, respectively). The AHG and FCXM results correlated with rejections and graft survivals whether testing pre-Tx or Hx high-PRA sera. Re-Tx recipients who were AHG-XM-NEG but FCXM-POS, experienced more rejection episodes than recipients who displayed a negative XM reactivity for both AHG and FCXM (P less than 0.02), but with no resulting differences in graft survival. HLA matching, pre-Tx blood transfusions and PRA did not impact on these crossmatch and graft survival results. Use of AHG and/or FCXMs for Re-Tx, but not primary, recipients should help to improve graft survival for these high-risk recipients. 相似文献